Recombinant MFG-E8 Protein for Tissue Fibrosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic liver diseases, including liver fibrosis, rely on therapeutic supplements like ursodeoxycholic acid and silymarin, which do not act as fundamental therapeutic agents, and recent compounds with anti-fibrosis effects have shown limited clinical efficacy, necessitating a more effective therapeutic approach.
Innovation Solution
A recombinant protein based on the milk fat globule-EGF factor 8 (MFG-E8) protein with an improved amino acid sequence (SEQ ID NO: 1) is developed, which is used to create a composition for preventing or treating tissue fibrosis, offering enhanced biocompatibility, reduced side effects, and ease of mass production and quality control.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional MFG-E8 protein is used for treating tissue fibrosis, then the treatment provides some therapeutic effect, but the efficacy is insufficient to restore tissue levels to near-normal conditions
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of the MFG-E8 protein to create a recombinant version with improved therapeutic efficacy. Specifically, the recombinant protein contains amino acid substitutions at positions 156-158 (changing from Lys-Gly-Asp to Lys-Glu-Asp), which enhances its ability to prevent and treat tissue fibrosis compared to the conventional protein sequence.
2Object-affected harmful factors
If therapeutic supplements like ursodeoxycholic acid and silymarin are used for chronic liver diseases, then liver cell damage is prevented, but fundamental therapeutic effects are not achieved
Solution Approach 1:
The patent replaces conventional low-molecular-weight therapeutic supplements with a recombinant protein therapy. This substitution transitions from small molecule compounds (ursodeoxycholic acid, silymarin) to a biologic agent (recombinant MFG-E8 protein), providing fundamental therapeutic effects by directly addressing the underlying fibrotic processes rather than merely preventing cell damage.
3Object-generated harmful factors
If compounds with anti-fibrosis effects are used in clinical trials, then some anti-fibrosis activity is observed, but significant disease-alleviating effects are not achieved
Solution Approach 1:
The patent creates a composite therapeutic approach by combining the recombinant MFG-E8 protein with specific amino acid modifications. The composite structure integrates the native MFG-E8 framework with optimized amino acid sequences at critical positions, resulting in a therapeutic agent with significantly enhanced disease-alleviating effects compared to conventional anti-fibrosis compounds.
Data Source
AI summary
The present invention relates to a recombinant protein for preventing or treating tissue fibrosis, which is based on milk fat globule-EGF factor 8 (MFG-E8) protein and comprises the amino acid sequence of SEQ ID NO: 1, and to a composition for preventing or treating tissue fibrosis, which comprises the recombinant protein. The level of the effect of preventing or treating tissue fibrosis by the recombinant protein of the present invention is significantly improved compared to that of conventional milk fat globule-EGF factor 8 (MFG-E8) protein, so that the level of tissue fibrosis can be restored to a level very close to that in normal tissue by the prevention and treatment of tissue fibrosis.